[Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)].
Until now, patients with a progressive prostatic cancer, in whom all therapies failed and the disease spread locally and distally, was considered "a lost patient"; because it did not exist an effective therapy easily to be used. The skeletal pain control is a serious problem and it is a great responsibility also for the Urologists especially if the patient has not a short survival time and the quality of life is very poor. Physicians feel the need for a systemic, well tolerated and effective therapy also for a long time, uniform and repeatable, able to be efficient for these patients. Strontium 89 chloride seems to offer all these possibilities and to be the best procedure for Urologist, Radiotherapists and Nuclear Specialists in order to satisfy the patients requirements. International research has shown Sr-849 Chloride is a powerful new therapy. Sr-89 Chloride is a radiopharmaceutical product for the treatment of painful metastases from prostatic cancer. It is a new treatment but its effectiveness is well documented and results are reported in the most important international literature. In our Department a clinical research has started and our purpose is to produce more data for a clinical and biological evaluation of the results, hoping that a similar research will extend as a multicenter study.
Dormia
E
E
Divisione di Urologia, Ente Ospedaliero S. Carlo Borromeo, Milano.
Mantovani
F
F
Minervini
S
S
Malagola
G
G
Castellani
R
R
Dormia
G
G
Gonnella
G
G
Mazza
L
L
Luongo
P
P
Bertana
F
F
D001859:Bone Neoplasms / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D002277:Carcinoma / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D008297:Male; D010146:Pain / Q000209:etiology; D011471:Prostatic Neoplasms / Q000473:pathology*; D011835:Radiation Protection; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013324:Strontium / Q000493:pharmacokinetics / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*
D013326:Strontium Radioisotopes; C025700:strontium chloride; D013324:Strontium
Trattamento delle metastasi ossee sintomatiche da carcinoma prostatico con Cloruro di Stronzio (Sr-89).